CARLSBAD, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced that the Company will present at the UBS Global Life Sciences Conference in New York, NY. B. Lynne Parshall, Executive Vice President and CFO, will provide an overview of the Company and an update on recent clinical and business activities.
The presentation will begin at 7:30 a.m. ET (4:30 a.m. PT) on Tuesday, September 26, 2006. To access the live audio webcast, log on to www.isispharm.com. In addition to the live webcast, the presentation will be archived for a limited time on the Company’s website.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world’s first antisense drug and has 15 drugs in development. Isis’ drug development programs are aimed at treating cardiovascular, metabolic and inflammatory diseases. Isis’ partners are focused in disease areas such as inflammatory, ocular, viral and neurodegenerative diseases, and cancer. In its Ibis division, Isis is developing and commercializing the Ibis T5000 biosensor system, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
This press release includes forward-looking statements related to Isis Pharmaceuticals, Inc., its clinical development pipeline and the potential value of the Company’s drug discovery technology platform. Any statement describing Isis’ goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis’ goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2005, and its quarterly report on Form 10-Q for the quarter ended June 30, 2006, which are on file with the SEC. Copies of these and other documents are available from the Company.
Isis Pharmaceuticals, Inc.
CONTACT: Kate Corcoran, Ph.D., VP, Corporate Development of IsisPharmaceuticals, Inc., +1-760-603-2712
Web site: http://www.isispharm.com/
